“Dose reduction of ibrutinib in chronic lymphocytic leukemia: long-term outcomes from a real-world single-center experience”, Mediterr J Hematol Infect Dis, vol. 18, no. 1, p. e2026090, Oct. 2026, doi: 10.4084/MJHID.2026.090.